Kinder Morgan, Inc. (NYSE:KMI) today announced that the deadline for
Kinder Morgan Energy Partners, L.P. (NYSE:KMP) and El Paso Pipeline
Partners, L.P. (NYSE:EPB) unitholders to elect the form of consideration
they wish to receive in each of KMP’s and EPB’s pending mergers with KMI
is 5:00 p.m. ET on Nov.
Exchange Traded Funds, sponsored and managed by Northern Trust, today
introduced FlexShares Credit‐Scored US Corporate Bond Index Fund
(Nasdaq: SKOR), a fixed income portfolio consisting of corporate debt
securities selected using a proprietary credit evaluation process.
plc (NYSE: MNK) has been informed by the U.S. Food and Drug
Administration (FDA) that the agency has reason to believe that the
company’s methylphenidate hydrochloride extended-release (ER) tablets,
USP (CII) may not be therapeutically equivalent to the category
reference drug Concerta®. As a result, the agency indicated that it has
reclassified Mallinckrodt’s ANDA 202608 for methylphenidate ER dosage
strengths of 27mg, 36 mg and 54 mg from AB (freely substitutable at the
pharmacy level) to BX (presumed to be therapeutically inequivalent). The
agency said that this change was based on the application of its new
Draft Guidance for determining bioequivalence of methylphenidate
hydrochloride products just published on November 6, 2014.
Pro Forma Results: - Adjusted Net Income of $35.5 Million or $0.40 per Fully Diluted Share for the Third Quarter; $116.2 Million or $1.31 per Fully Diluted Share for the First Nine Months 2014
- Adjusted EBITDA of $57.8 Million for the Third Quarter; $193.7 Million for the First Nine Months 2014 Assets Under Administration of $212.8 Billion; up 11.3% From the Year Ago Period Following Review by Independent External Counsel and Forensic Accounting Firm, RCS Capital's Audit Committee and Management Team Remain Confident in The Company's Reported Historical Financials, Accounting, and Internal Controls $57 - $65 Million Revenue Synergies and Cost Savings Expected to be in Place for January 1, 2015; Additional Synergies Expected in 2015 9,139 Total Advisors on Platform; 97.8% Annualized Advisor Retention; Solid Retail Margin Expansion in Third Quarter; Robust Recruiting Pipeline Wholesale Distribution Equity Sales of $2.3 Billion for the Third Quarter; $8.2
By Jennifer Booton, MarketWatch DJI introduces the Inspire 1, its newest mid-tier consumer drone
NEW YORK (MarketWatch) -- If you thought drones were just for hobbyists or CIA spies, you thought wrong.
By Philip van Doorn, MarketWatch The benchmark index, meanwhile, sets records over five consecutive days
Do you remember the "bubble" warnings after the S&P 500 Index (SPX) hit an intraday high on Sept.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from
several Phase 2 and Phase 3 studies evaluating investigational uses of
Harvoni ® (ledipasvir 90 mg/sofosbuvir 400 mg) for the
treatment of chronic hepatitis C virus (HCV) infection in patients with
limited or no treatment options, including patients with decompensated
cirrhosis, patients with HCV recurrence following a liver transplant and
patients who failed previous treatment with other direct acting
Nuveen Investments, a leading global provider of investment services to
institutions as well as individual investors, today announced
distributions for the Nuveen Global Income Opportunities Fund (NYSE:
JGG) and Nuveen Diversified Currency Opportunities Fund (NYSE: JGT). The
specific distribution dates and amounts are detailed below.
Under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, the Qualified Infectious Disease Product (QIDP) designation allows for additional five years of market exclusivity in addition to existing exclusivity, Fast-Track status (an expedited development pathway) and Priority Review status (shortened review time for marketing applications) With half of the targeted 120 patients already recruited, top-line data from the ongoing RHB-105 first Phase III study in the U.S. is expected in the second quarter of 2015 RHB-105 is targeting a significantly broader indication than that of existing H.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.